ArticleMedicine2026
Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design of a novel multiepitope vaccine against glioblastoma by in silico approaches.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiotherapy for newly diagnosed glioblastoma (GBM) patients, as well as analyzing the prognostic factors for these patients, can provide valuable data to guide the clinical application of TTFields.
methodsThis study retrospectively analyzed the clinical treatment of 68 GBM patients receiving the TTFields, admitted to the Department of Radiation Oncology at Jiangsu Cancer Hospital from September 2021 to October 2024. Progression-free survival (PFS) curves and overall survival were constructed using the Kaplan-Meier method. A Cox proportional hazards regression model was used to assess the effect of TTFields and to account for confounding factors.
resultsAmong the 68 GBM patients included in the study, the median PFS was 16.4 months (95% CI: 13.3-19.5), the median overall survival was 28.8 months (95% CI: 20.6-37.0) for all 68 patients. The objective response rate was 64.7% (44/68), and the disease control rate was 94.1% (64/68). Multivariate analysis revealed that surgery type and compliance rate with TTFs were favorable prognostic factors. Mild to moderate skin toxicity underneath the transducer arrays occurred in 51.4% of patients.
conclusionIn our final analysis of single-center Chinese patients with newly diagnosed GBM, concurrent chemoradiotherapy with TTFields resulted in promising PFS outcomes that warrant validation in propensity-matched or randomized studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.